We are a clinical-stage biopharmaceutical company focused on neuroscience.
We translate novel scientific insights into new medicines. That’s a drastic challenge. Our work is complex, risky, labor-intensive, persistent and expensive. And it’s what we love to do.
A key focus of our R&D is to develop first-in-class medicines for people with debilitating neurodegenerative conditions. In fact,
Our mission is to detect and treat Alzheimer's disease.
What if detecting Alzheimer’s was as simple as getting a blood test? We’re working on that too.
Our Work is Urgent.
Over 5 million people have Alzheimer's disease in the U.S. today. This number will increase significantly in the years ahead.
Yet Alzheimer's disease is uncurable.
New drugs for Alzheimer's remain elusive. A long-prevailing scientific hypothesis - clearing amyloid from the brain - has led to high-profile clinical failures. It is unlikely that any one drug will successfully treat Alzheimer's disease.
All this makes the case to consider the development of new and promising approaches for the treatment and diagnosis of Alzheimer's disease.
Collaboration is key.
Unraveling Alzheimer's disease is a hard problem. It requires collaboration.
The National Institutes of Health (NIH) continues to provide our research programs with substantial scientific and financial support. Academics and scientific and medical advisors supply us with substantial technical support.
Together, we are setting a new course to develop therapies that can help improve human health.